➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Dow
Johnson and Johnson
Moodys
McKinsey

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

GRISEOFULVIN, ULTRAMICROSIZE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Griseofulvin, Ultramicrosize, and what generic alternatives are available?

Griseofulvin, Ultramicrosize is a drug marketed by Mountain and Sandoz Inc and is included in two NDAs.

The generic ingredient in GRISEOFULVIN, ULTRAMICROSIZE is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.

US ANDA Litigation and Generic Entry Outlook for Griseofulvin, Ultramicrosize

A generic version of GRISEOFULVIN, ULTRAMICROSIZE was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.

  Start Trial

Summary for GRISEOFULVIN, ULTRAMICROSIZE
Drug patent expirations by year for GRISEOFULVIN, ULTRAMICROSIZE
Pharmacology for GRISEOFULVIN, ULTRAMICROSIZE

US Patents and Regulatory Information for GRISEOFULVIN, ULTRAMICROSIZE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mountain GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 204371-001 Jan 9, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Sandoz Inc GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 202805-002 Dec 26, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Mountain GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 204371-002 Jan 9, 2014 AB RX No Yes   Start Trial   Start Trial   Start Trial
Sandoz Inc GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 202805-001 Dec 26, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Dow
Merck
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.